Remsima is named as an intervention in 4 current clinical trials in our Netherlands, France, Spain, Belgium and Israel registers. 2 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Celltrion (1). The most-studied condition is Crohn Disease.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease
NCT06059989 · ClinicalTrials.gov ↗ · Inflammatory Disease, Disease Crohn, Bowel Disease
|
Phase 3 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Netherlands |
|
Post-Operative Crohn's Disease Outcome in Children
NCT03681652 · ClinicalTrials.gov ↗ · Crohn Disease
|
Observational | Recruiting | Schneider Children's Medical Center, Israel | Israel |
|
De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease
NCT04646187 · ClinicalTrials.gov ↗ · Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative
|
Phase 4 | By invitation | University Medical Center Groningen | Spain, Netherlands, Belgium |
|
A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps
NCT05866614 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
|
Observational | Active, closed | Celltrion | France |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Celltrion | 1 |
| University Medical Center Groningen | 1 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Schneider Children's Medical Center, Israel | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Netherlands | 2 | 1 |
| Clinical trials in France | 1 | 0 |
| Clinical trials in Spain | 1 | 0 |
| Clinical trials in Belgium | 1 | 0 |
| Clinical trials in Israel | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our Netherlands, France, Spain, Belgium and Israel registers name Remsima as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 4 trials are recruiting: 1 with sites in Netherlands and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Celltrion (1), University Medical Center Groningen (1), Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) and Schneider Children's Medical Center, Israel (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Remsima works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Remsima works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Remsima (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.